"Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Geburtshilfe, Brustzentrum"
Welcome,         Profile    Billing    Logout  
 5 Trials 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thill, Marc
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study).

Recruiting
4
150
Europe
Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
German Breast Group, Pfizer, AMS Advanced Medical Services GmbH
Metastatic Breast Cancer
03/23
03/23
EMBER-3, NCT04975308: Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Not yet recruiting
3
500
Europe, Japan, US, RoW
LY3484356, Exemestane, Fulvestrant
Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
03/23
03/26
eMonarcHER, NCT04752332 / 2020-004035-24: A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Checkmark [VIRTUAL] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Recruiting
3
2450
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Standard Adjuvant ET, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms
05/25
02/33
Keyriched-1, NCT03988036: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Recruiting
2
46
Europe
Pembrolizumab, Keytruda®, Trastuzumab Biosimilar ABP 980, Trazimera®, Pertuzumab, Perjeta®
West German Study Group, Merck Sharp & Dohme Corp., NanoString Technologies, Inc.
Breast Cancer
08/21
12/21
PULSE, NCT03975855: Evaluation of NeoNavia® Biopsy System in Axillary Lymph Nodes

Checkmark [VIRTUAL] One size fits all? Novel pulse biopsy platform offers improved needle control, high tissue yield and multiple needle options – pre-clinical results
Active, not recruiting
N/A
140
Europe
NeoNavia® Biopsy System
NeoDynamics AB
Breast Cancer
06/21
06/21
Brandi, Christiane
Keyriched-1, NCT03988036: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Recruiting
2
46
Europe
Pembrolizumab, Keytruda®, Trastuzumab Biosimilar ABP 980, Trazimera®, Pertuzumab, Perjeta®
West German Study Group, Merck Sharp & Dohme Corp., NanoString Technologies, Inc.
Breast Cancer
08/21
12/21

Download Options